Just reported
From Illumina's results release of 29 oktober 2026; its quarterly report has since been filed.
Actual
US$ 1,13B
+4,2% y/y
-2,6% q/q
Guided
—
No guide given
Actual
US$ 1,43
+46% y/y
+5,9% q/q
Guided
—
No guide given
Actual
US$ 305M
+34% y/y
+24% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
De omzetaandelen zijn schattingen voor quarter ended 2026-03-31, geen cijfers uit een ingediend rapport.
NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.
StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.
Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.
Gebouwd uit de eigen deponeringen van Illumina, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
US$ 209,61-1,5%slot 12 nov
Cijfers tot en met 27 september 2026, uit de 10-Q ingediend op 30 oktober 2026
Illumina sells DNA-sequencing kits and machines to medical laboratories, hospitals, universities and drug companies.
The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
De balk onder de koers toont het cijfer op elke datum, alleen gebaseerd op de stukken die toen al openbaar waren.
Toont 2 van 41 kwartalen van de cijferhistorie van Illumina, Inc.. De andere 39 lopen terug tot november 2016.
